GTG Labs (GENE): Utang-utang marang kapitalisasi buku

Tandha merek gtglabs.com (GENE)

This debt-to-market cap chart illustrates the scaling potential of Genetic Technologies (GENE) through the global licensing of proprietary diagnostic methodologies. Meanwhile, 0.48 captures the magnitude of this parameter, accounting for a moderate dependence on external IT providers and logistics firms. However, the small size of the business creates risks of losing market share under pressure from industry behemoths in the oncology screening segment.

GENE Rasio utang marang nilai buku Genetic Technologies Limited (04.07.2022 - 26.10.2024)

Ringkesan rincian data analitis gtglabs.com (GENE)

- rega lan prakiraan konsensus rega:
Rega saham Genetic Technologies Limited|GENE - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Kapitalisasi pasar Genetic Technologies Limited|GENE - Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Genetic Technologies|GENE - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku gtglabs.com|GENE - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Genetic Technologies|GENE - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Genetic Technologies Limited|GENE - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Genetic Technologies Limited
Ringkesan analitik perusahaan:GTG Labs
Produk asli Genetic Technologies Ltd

Genetic Technologies is actively expanding the presence of geneType IT tests within the B2B clinic segment. GURU.Markets tools allow for tracking the dynamics of the debt-to-capitalization ratio during this process. This metric compares total debt with the book value of assets to evaluate the financing structure. A decrease in the ratio minimizes credit risks, whereas excess equity may indicate an underutilization of leverage. This determines financial stability during business expansion.

Pesaing Genetic Technologies

A - Utang-utang marang kapitalisasi buku|Rasio utang marang nilai buku questdiagnostics.com DGX|Illumina - Utang-utang marang kapitalisasi buku|EXAS: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku PerkinElmer|Bio-Rad Corp (BIO) - Rasio utang marang nilai buku|NNNN (Anbio Biotechnology) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku SHC|Rasio utang marang kapitalisasi buku QuidelOrtho Corporation (QDEL)|Rasio utang marang kapitalisasi buku OPKO Health Inc OPK|CDNA: Utang marang nilai buku|Maravai - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku FLGT (Fulgent Genetics, Inc.)|LAB - Utang-utang marang aset resik|Cytek Biosciences - Utang-utang marang kapitalisasi buku|OSUR (OraSure Technologies, Inc.) - Utang-utang marang aset resik|XGN: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik MDxHealth, Inc.|LUCD: Utang-utang marang kapitalisasi buku|Utang marang aset resik prenetics.com (PRE)|IMDX: Utang-utang marang kapitalisasi buku|Trinity Biotech PLC - Utang-utang marang nilai buku|ProPhase (PRPH) - Rasio utang marang kapitalisasi buku|AIMD - Rasio utang marang nilai buku|Utang-utang marang kapitalisasi buku CODX|Utang-utang marang nilai buku heartsciences.com|Biomerica (BMRA) - Utang marang nilai buku|Utang marang modal buku Cardio Diagnostics Holdings, Inc.|VRAX (Virax Biolabs Group Ltd) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Bluejay Diagnostics Corp (BJDX)|Aspira Women's Health - Utang-utang marang kapitalisasi buku|AXDX - Utang marang nilai buku|Utang marang nilai buku CENTOGENE (CNTG)|Enzo Biochem, Inc. (ENZ) - Rasio utang marang aset resik|FRES - Utang marang nilai buku|23andMe Inc (ME) - Utang marang modal buku|Utang-utang marang kapitalisasi buku PMD (Psychemedics)